0001280600-20-000020.txt : 20200406 0001280600-20-000020.hdr.sgml : 20200406 20200406084152 ACCESSION NUMBER: 0001280600-20-000020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200403 ITEM INFORMATION: Other Events FILED AS OF DATE: 20200406 DATE AS OF CHANGE: 20200406 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 20775847 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 xlrn-20200403form8xk.htm 8-K Document
false0001280600 0001280600 2020-04-03 2020-04-03


 
 
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
___________________________
 
FORM 8-K
___________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  April 3, 2020
 ___________________________
 
ACCELERON PHARMA INC.
(Exact name of Registrant as specified in its charter)
 

Delaware
 
001-36065
 
27-0072226
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification Number)

128 Sidney Street
 
 
 
 
Cambridge,
MA
 
 
 
02139
(Address of principal
executive offices)
 
 
 
(Zip Code)
 

Registrant’s telephone number, including area code:  (617) 649-9200
 
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Ticker Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 per share
XLRN
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company           
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.           

 
 
 
 
 





Item 8.01    Other Events.
 
On April 3, 2020, Acceleron Pharma Inc. and Bristol-Myers Squibb announced that the U.S. Food and Drug Administration has approved REBLOZYL ® (luspatercept-aamt), the first and only erythroid maturation agent, for the treatment of anemia failing an erythropoiesis stimulating agent and requiring two or more red blood cell units over eight weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.


2



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
ACCELERON PHARMA INC.
 
 
 
 
 
By:
/s/ Adam M. Veness, Esq.
 
 
Adam M. Veness, Esq.
 
 
Senior Vice President, General Counsel and Secretary
 
 
 
Date: April 6, 2020
 
 


3
EX-101.SCH 2 xlrn-20200403.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 xlrn-20200403_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 xlrn-20200403_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 xlrn-20200403_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 6 xlrn-20200403_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT JSON 7 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "xlrn-20200403form8xk.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "xlrn-20200403_cal.xml" ] }, "definitionLink": { "local": [ "xlrn-20200403_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "xlrn-20200403form8xk.htm" ] }, "labelLink": { "local": [ "xlrn-20200403_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "xlrn-20200403_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "xlrn-20200403.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "xlrn", "nsuri": "http://www.acceleronpharma.com/20200403", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "xlrn-20200403form8xk.htm", "contextRef": "D2020Q2SD-APR03-APR03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.acceleronpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "xlrn-20200403form8xk.htm", "contextRef": "D2020Q2SD-APR03-APR03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acceleronpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.acceleronpharma.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports xlrn-20200403form8xk.htm xlrn-20200403.xsd xlrn-20200403_cal.xml xlrn-20200403_def.xml xlrn-20200403_lab.xml xlrn-20200403_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true XML 13 xlrn-20200403form8xk_htm.xml IDEA: XBRL DOCUMENT 0001280600 2020-04-03 2020-04-03 false 0001280600 8-K 2020-04-03 ACCELERON PHARMA INC. DE 001-36065 27-0072226 128 Sidney Street Cambridge, MA 02139 617 649-9200 false false false false Common Stock, $0.001 per share XLRN NASDAQ false ZIP 14 0001280600-20-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001280600-20-000020-xbrl.zip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htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page
Apr. 03, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 03, 2020
Entity Registrant Name ACCELERON PHARMA INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36065
Entity Tax Identification Number 27-0072226
Entity Address, Address Line One 128 Sidney Street
Entity Address, City or Town Cambridge,
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 649-9200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 per share
Trading Symbol XLRN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001280600
Amendment Flag false